Nct00105300

Biological Therapies for Inflammatory Bowel Diseases | Paul Rutgeerts

Biological Therapies for Inflammatory Bowel Diseases | Paul Rutgeerts

Selecting appropriate anti-TNF agents in inflammatory bowel disease

Selecting appropriate anti-TNF agents in inflammatory bowel disease

Identification of inflammatory mediators in patients with Crohn's

Identification of inflammatory mediators in patients with Crohn's

Loss of Response and Requirement of Infliximab Dose Intensification

Loss of Response and Requirement of Infliximab Dose Intensification

Efficacy of adalimumab in sarcoidosis patients who developed

Efficacy of adalimumab in sarcoidosis patients who developed

Switching to adalimumab for psoriasis patients with a suboptimal

Switching to adalimumab for psoriasis patients with a suboptimal

A Phase 2 Study of Tofacitinib, an Oral Janus Kinase Inhibitor, in

A Phase 2 Study of Tofacitinib, an Oral Janus Kinase Inhibitor, in

Perianal Fistulas in Patients With Crohn's Disease, Part 1: Current

Perianal Fistulas in Patients With Crohn's Disease, Part 1: Current

Comparative Effectiveness of Anti-TNF Agents for Crohn's Disease in

Comparative Effectiveness of Anti-TNF Agents for Crohn's Disease in

Galapagos NV: JAK and the giant opportunity - Initiating at OW with

Galapagos NV: JAK and the giant opportunity - Initiating at OW with

Unresolved issues in identifying and overcoming inadequate response

Unresolved issues in identifying and overcoming inadequate response

Older Age Is Associated with Higher Rate of Discontinuation of Anti

Older Age Is Associated with Higher Rate of Discontinuation of Anti

Systematic Assessment of Factors Influencing Preferences of Crohnʼs

Systematic Assessment of Factors Influencing Preferences of Crohnʼs

Identification of inflammatory mediators in patients with Crohn's

Identification of inflammatory mediators in patients with Crohn's

A Randomized Trial of Ustekinumab, a Human Interleukin-12/23

A Randomized Trial of Ustekinumab, a Human Interleukin-12/23

Adalimumab for Crohn's disease with intolerance or lost response to

Adalimumab for Crohn's disease with intolerance or lost response to

Anti-TNF-alpha treatments and obstructive symptoms in Crohn's

Anti-TNF-alpha treatments and obstructive symptoms in Crohn's

Review article: a clinician's guide for therapeutic drug monitoring

Review article: a clinician's guide for therapeutic drug monitoring

Interleukin-15 and Its Soluble Receptor Mediate the Response to

Interleukin-15 and Its Soluble Receptor Mediate the Response to

Update on Ustekinumab for the Treatment of Crohn's Disease | Yvette

Update on Ustekinumab for the Treatment of Crohn's Disease | Yvette

Biologics in General Medicine | J  Salfeld | Request PDF

Biologics in General Medicine | J Salfeld | Request PDF

Investigation of the Prognostic Value of TNF-α Gene Polymorphism

Investigation of the Prognostic Value of TNF-α Gene Polymorphism

Biological Therapies for Inflammatory Bowel Diseases | Paul Rutgeerts

Biological Therapies for Inflammatory Bowel Diseases | Paul Rutgeerts

Adalimumab Reduces Extraintestinal Manifestations in Patients with

Adalimumab Reduces Extraintestinal Manifestations in Patients with

Vedolizumab as a Rescue Therapy for Patients with Medically

Vedolizumab as a Rescue Therapy for Patients with Medically

Efficacy of Vedolizumab as Induction Therapy in Refractory IBD

Efficacy of Vedolizumab as Induction Therapy in Refractory IBD

Unresolved issues in identifying and overcoming inadequate response

Unresolved issues in identifying and overcoming inadequate response

The Incidence and Predictors of Lupus-like Reaction in Patients with

The Incidence and Predictors of Lupus-like Reaction in Patients with

Monitoring Functional Serum Antitumor Necrosis Factor Antibody Level

Monitoring Functional Serum Antitumor Necrosis Factor Antibody Level

Dosage Adjustment During Long-term Adalimumab Treatment for Crohn's

Dosage Adjustment During Long-term Adalimumab Treatment for Crohn's

A Randomized Trial of Ustekinumab, a Human Interleukin-12/23

A Randomized Trial of Ustekinumab, a Human Interleukin-12/23

Biologic Treatment of Crohn's Disease: Adalimumab

Biologic Treatment of Crohn's Disease: Adalimumab

Clinical experience with infliximab and adalimumab in a single

Clinical experience with infliximab and adalimumab in a single

A Retrospective Comparison of Infliximab vs Adalimumab as Induction

A Retrospective Comparison of Infliximab vs Adalimumab as Induction

Systematic review: The short-term and long-term efficacy of

Systematic review: The short-term and long-term efficacy of

Biological Therapies for Inflammatory Bowel Diseases | Paul Rutgeerts

Biological Therapies for Inflammatory Bowel Diseases | Paul Rutgeerts

Investigation of the Prognostic Value of TNF-α Gene Polymorphism

Investigation of the Prognostic Value of TNF-α Gene Polymorphism

Use of a third anti-TNF after failure of two previous anti-TNFs in

Use of a third anti-TNF after failure of two previous anti-TNFs in

Comprehensive review: Antitumor necrosis factor agents in

Comprehensive review: Antitumor necrosis factor agents in

Anti-TNF therapy for paediatric IBD: The Scottish national

Anti-TNF therapy for paediatric IBD: The Scottish national

Oral administration of an ethanolic extract of Hypericum

Oral administration of an ethanolic extract of Hypericum

A Retrospective Comparison of Infliximab vs Adalimumab as Induction

A Retrospective Comparison of Infliximab vs Adalimumab as Induction

Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate

Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate

Efficacy and Safety of Tumor Necrosis Factor Antagonists in Crohn's

Efficacy and Safety of Tumor Necrosis Factor Antagonists in Crohn's

Vedolizumab: an 4 7 integrin antagonist for ulcerative colitis and

Vedolizumab: an 4 7 integrin antagonist for ulcerative colitis and

Long-term outcome of adalimumab therapy for ulcerative colitis with

Long-term outcome of adalimumab therapy for ulcerative colitis with

Sequential use of biologics in the treatment of moderate-to-severe

Sequential use of biologics in the treatment of moderate-to-severe

PDF) Adalimumab induction therapy for Crohn disease previously

PDF) Adalimumab induction therapy for Crohn disease previously

Long-term safety and efficacy of certolizumab pegol in the treatment

Long-term safety and efficacy of certolizumab pegol in the treatment

Addition of an Immunomodulator to Infliximab Therapy Eliminates

Addition of an Immunomodulator to Infliximab Therapy Eliminates

Biological Therapies for Inflammatory Bowel Diseases | Paul Rutgeerts

Biological Therapies for Inflammatory Bowel Diseases | Paul Rutgeerts

Range of Bowel Diseases Can Be Treated with Humira

Range of Bowel Diseases Can Be Treated with Humira

Efficacy of adalimumab in sarcoidosis patients who developed

Efficacy of adalimumab in sarcoidosis patients who developed

Certolizumab Pegol for the Management of Crohn's Disease in Adults

Certolizumab Pegol for the Management of Crohn's Disease in Adults

PDF) Adalimumab in clinical practice  Outcome in 70 rheumatoid

PDF) Adalimumab in clinical practice Outcome in 70 rheumatoid

Health-economic analysis: Cost-effectiveness of scheduled

Health-economic analysis: Cost-effectiveness of scheduled

Update on Ustekinumab for the Treatment of Crohn's Disease | Yvette

Update on Ustekinumab for the Treatment of Crohn's Disease | Yvette

Anti-TNF-alpha treatments and obstructive symptoms in Crohn's

Anti-TNF-alpha treatments and obstructive symptoms in Crohn's

A 10-Year, Single Tertiary Care Center Experience on the Durability

A 10-Year, Single Tertiary Care Center Experience on the Durability

Cost-effectiveness of biological treatment sequences for fistulising

Cost-effectiveness of biological treatment sequences for fistulising

Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate

Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate

Overview of stem cell therapy for Crohn's disease | Gerald Wayne

Overview of stem cell therapy for Crohn's disease | Gerald Wayne

The Value of Vedolizumab as Rescue Therapy in Moderate-Severe

The Value of Vedolizumab as Rescue Therapy in Moderate-Severe

Optimizing drug therapy in inflammatory bowel disease | Arun

Optimizing drug therapy in inflammatory bowel disease | Arun

Biological Therapies for Inflammatory Bowel Diseases | Paul Rutgeerts

Biological Therapies for Inflammatory Bowel Diseases | Paul Rutgeerts

Performance of Crohn's disease Clinical Trial Endpoints based upon

Performance of Crohn's disease Clinical Trial Endpoints based upon

Efficacy of adalimumab in sarcoidosis patients who developed

Efficacy of adalimumab in sarcoidosis patients who developed

Unresolved issues in identifying and overcoming inadequate response

Unresolved issues in identifying and overcoming inadequate response

Adalimumab for Crohn's disease: Long-term sustained benefit in a

Adalimumab for Crohn's disease: Long-term sustained benefit in a

Frequency and predictors of loss of response to biological therapy

Frequency and predictors of loss of response to biological therapy

Interleukin-15 and Its Soluble Receptor Mediate the Response to

Interleukin-15 and Its Soluble Receptor Mediate the Response to

Biological Therapies for Inflammatory Bowel Diseases | Paul Rutgeerts

Biological Therapies for Inflammatory Bowel Diseases | Paul Rutgeerts

Comprehensive review: Antitumor necrosis factor agents in

Comprehensive review: Antitumor necrosis factor agents in

Long-term outcome of a third anti-TNF monoclonal antibody after the

Long-term outcome of a third anti-TNF monoclonal antibody after the

Biologic therapy in Crohn's disease: State of the art | Jennifer Jones

Biologic therapy in Crohn's disease: State of the art | Jennifer Jones

Tu1158 Evaluating Adalimumab Drug and Antibody Levels As Predictors

Tu1158 Evaluating Adalimumab Drug and Antibody Levels As Predictors

Cost-effectiveness of biological treatment sequences for fistulising

Cost-effectiveness of biological treatment sequences for fistulising

Global rates of Crohn's Disease | Marcel A Behr

Global rates of Crohn's Disease | Marcel A Behr

Identification of inflammatory mediators in patients with Crohn's

Identification of inflammatory mediators in patients with Crohn's

Anti-TNF-alpha treatments and obstructive symptoms in Crohn's

Anti-TNF-alpha treatments and obstructive symptoms in Crohn's

Adalimumab induction therapy for Crohn disease previously treated

Adalimumab induction therapy for Crohn disease previously treated

Individual medicine in inflammatory bowel disease: Monitoring

Individual medicine in inflammatory bowel disease: Monitoring

Biological Therapies for Inflammatory Bowel Diseases | Paul Rutgeerts

Biological Therapies for Inflammatory Bowel Diseases | Paul Rutgeerts

Predictors of dose escalation of adalimumab in a prospective cohort

Predictors of dose escalation of adalimumab in a prospective cohort

Retrospective Evaluation of the Safety and Effect of Adalimumab

Retrospective Evaluation of the Safety and Effect of Adalimumab

PDF) Adalimumab in clinical practice  Outcome in 70 rheumatoid

PDF) Adalimumab in clinical practice Outcome in 70 rheumatoid

Update on Ustekinumab for the Treatment of Crohn's Disease | Yvette

Update on Ustekinumab for the Treatment of Crohn's Disease | Yvette

Adalimumab Reduces Extraintestinal Manifestations in Patients with

Adalimumab Reduces Extraintestinal Manifestations in Patients with

Systematic review with network meta-analysis: The efficacy of anti

Systematic review with network meta-analysis: The efficacy of anti

Dosage Adjustment During Long-term Adalimumab Treatment for Crohn's

Dosage Adjustment During Long-term Adalimumab Treatment for Crohn's

Use of a third anti-TNF after failure of two previous anti-TNFs in

Use of a third anti-TNF after failure of two previous anti-TNFs in

Guidance on the use of adalimumab for juvenile idiopathic arthritis

Guidance on the use of adalimumab for juvenile idiopathic arthritis

Identification of inflammatory mediators in patients with Crohn's

Identification of inflammatory mediators in patients with Crohn's

A Retrospective Comparison of Infliximab vs Adalimumab as Induction

A Retrospective Comparison of Infliximab vs Adalimumab as Induction

Older Age Is Associated with Higher Rate of Discontinuation of Anti

Older Age Is Associated with Higher Rate of Discontinuation of Anti

Retrospective Evaluation of the Safety and Effect of Adalimumab

Retrospective Evaluation of the Safety and Effect of Adalimumab

The efficacy and safety of a third anti-TNF monoclonal antibody in

The efficacy and safety of a third anti-TNF monoclonal antibody in